The global cell harvesting system market is poised for significant growth, with an estimated market value of US$ 6.9 billion in 2025 and a projected reach of US$ 15.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of 12.2% during the forecast period from 2025 to 2032. Cell harvesting, the process of isolating target cells from growth media, is a critical component in biologic manufacturing. While historically reliant on manual methods such as centrifugation and depth filtration, the sector has undergone a technological transformation, driven by advancements in automation and improved systems designed to enhance throughput, scalability, and process control.
The market is being fueled by growing demand for regenerative medicine, personalized therapies, and cell-based treatments, coupled with increasing investments in artificial intelligence (AI) and healthcare infrastructure. These drivers have fostered rapid innovation and increased demand for more efficient, precise, and scalable cell harvesting solutions, positioning the sector for substantial growth.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34752
Key Industry Highlights:
Automated systems are expected to dominate the market, capturing 67.4% of the market share by 2025, surpassing manual systems due to superior efficiency, precision, and scalability.
The growing application of regenerative medicine, stem cell therapies, and cell-based treatments continues to push the demand for advanced cell harvesting systems.
Innovations in cell harvesting technologies, such as automated harvesters and improved filtration systems, are enhancing the accuracy and reliability of the harvesting process.
Strategic partnerships, mergers, and acquisitions among key players have spurred innovation and market expansion.
The biopharmaceutical sector is poised to be a major contributor, driven by the increasing demand for personalized therapies, vaccines, and advanced biomanufacturing.
North America is expected to lead the global market with a 38.6% value share in 2025, thanks to its strong biopharmaceutical infrastructure and continuous investments in cell-based research.
Market Dynamics
Driver – Automation and Innovation Fuels Global Growth
A major driver of growth in the cell harvesting system market is the advancement of automation technologies and the increased use of single-use systems. Automated systems streamline workflows, enhance process reproducibility, and reduce human error, which are critical for scaling production and ensuring consistency in biologic manufacturing.
Noteworthy examples of innovation include the launch of the DynaSpin Single-Use Centrifuge by Thermo Fisher Scientific in October 2022, which reduces filter usage by up to six-fold and minimizes waste. Similarly, in May 2024, Cytiva partnered with Kite (Gilead) to introduce the Sefia cell therapy manufacturing platform, an automated solution that integrates multiple manufacturing steps—from cell isolation to expansion—in a closed, digitally controlled environment.
The growing use of automated tangential flow filtration (TFF) and continuous centrifuges has further enhanced the industry’s ability to monitor and control processes in real time, which reduces the costs and timelines associated with biologic production.
Restraint – High Costs and Legacy Systems Limit Adoption
Despite the promising benefits, the adoption of automated cell harvesting technologies faces certain barriers. High costs associated with advanced systems, coupled with the complexity of system qualification and integration, are significant factors limiting widespread adoption. Many biopharmaceutical companies still rely on legacy systems, including manual centrifugation, due to prior capital investments and familiarity with existing technologies. The transition to automated systems often requires multiple test runs and adjustments, delaying implementation.
In addition, regulatory challenges and the need for extensive validation of new equipment further hinder the broader adoption of these advanced solutions. These factors contribute to a slower-than-expected uptake, especially in facilities with limited budgets or those operating under stringent regulatory environments.
Opportunity – Emerging Solutions in Biomanufacturing and Regenerative Medicine
The emergence of novel cell-harvesting technologies presents significant opportunities in the global market. In particular, the integration of robotic arms in cell culture systems, and the development of bioreactor technologies, have opened new avenues for pluripotent stem cell production. These innovations are essential for developing personalized cell therapies and advancing disease modeling.
In November 2024, Rousselot and IamFluidics launched a dissolvable microcarrier using patented IN-AIR MICROFLUIDICS™ technology, which simplifies adherent cell harvesting for large-scale applications. Similarly, devices such as the CellCelector by AVISO are enabling automated, precise cell selection, further enhancing the scalability of biomanufacturing operations.
The use of AI and machine learning technologies, combined with lab-on-a-chip solutions, is expected to optimize yield and scalability, positioning the sector for strong growth in regenerative medicine and biomanufacturing.
Category-wise Analysis
Product Insights
The segment of automated cell harvesters is forecast to capture the largest market share in 2025, with a projected 67.4% revenue share. The superior efficiency and precision of automated systems compared to manual techniques are key factors driving their adoption. Automated systems minimize labor costs, reduce human error, and increase throughput, making them ideal for high-volume applications in both research and clinical settings. As the demand for advanced therapies and personalized medicine continues to grow, automated systems are becoming essential tools in the development and production of cell-based treatments.
Application Insights
The biopharmaceutical sector is expected to account for a significant share of the market in 2025, driven by the increasing demand for monoclonal antibodies, vaccines, and cell-based therapies. Cell harvesting systems are integral to the production of these advanced therapies, enabling the efficient isolation and purification of therapeutic cells. The ongoing investments in biotech research and drug development further underscore the growing importance of these technologies in biopharmaceutical manufacturing.
Regional Insights
North America
North America is poised to dominate the global market in 2025, with an estimated 38.6% value share. The region benefits from a strong biopharmaceutical infrastructure, ongoing investments in cell-based research, and a robust network of research institutions and biotech companies. Government initiatives and favorable regulatory environments have played a pivotal role in fostering innovation and accelerating the adoption of advanced cell harvesting technologies. The U.S. continues to lead the global R&D spending, and numerous biopharmaceutical companies are investing heavily in the development of personalized medicine and cell therapies.
Europe
Europe is emerging as a major growth hub for the cell harvesting systems market, owing to its supportive regulatory environment, strategic investments in biomanufacturing, and increasing R&D funding. In 2023, Novartis launched a new GMP-ready cell culture manufacturing line in Austria, underscoring the region’s commitment to advancing its cell therapy infrastructure. With significant research funding and favorable regulatory frameworks, Europe is well-positioned to accelerate the development of innovative cell harvesting technologies.
Asia Pacific
The Asia Pacific market is experiencing rapid growth due to expanding biotech hubs and increased government funding for regenerative medicine research. For instance, in December 2023, FUJIFILM Corporation invested US$ 200 million in enhancing its cell therapy capabilities, further supporting the growing demand for advanced therapies in the region. Government support, coupled with an expanding middle class and increasing healthcare access, is expected to drive significant growth in the Asia Pacific market.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34752
Competitive Landscape
The global cell harvesting system market is characterized by a mix of established players and innovative startups. Companies are competing through technological advancements, strategic partnerships, and acquisitions to expand their market reach and capabilities.
Key Industry Developments:
Sphere Fluidics launched Cyto?Mine Chroma, a platform designed for high-throughput single-cell analysis, enhancing automated isolation and harvesting in biopharma workflows.
Ori Biotech Ltd. partnered with Fresenius Kabi to integrate the IRO® platform with the Cue® and Lovo® systems, streamlining cell therapy manufacturing.
Key Players
Esco Micro Pte. Ltd.
Sartorius AG
Cytiva (Danaher)
Beckman Coulter, Inc.
Thermo Fisher Scientific Inc.
Corning Incorporated
PerkinElmer
Smart MCs PTY LTD
Revvity
Recent Developments
In 2024, the industry saw significant innovations, such as AVITA Medical’s development of advanced microfluidic systems, while Sartorius AG unveiled a next-generation filtration technology to boost throughput and minimize cell loss. These innovations signal a promising future for the sector, with continuous investments pushing the envelope of what is possible in cell harvesting.
Future Outlook
The future of the global cell harvesting system market is promising, with the increasing adoption of automated technologies and the rise of regenerative medicine continuing to drive growth. As the demand for personalized medicine and cell therapies escalates, the need for more efficient, scalable, and cost-effective cell harvesting solutions will become even more critical. With technological innovations, strategic partnerships, and robust investments from key players, the market is set to witness sustained growth over the next decade.
